100% agree. $3.20 is ridiculous, especially considering we were $3.60-$3.70 prior to the Arcadia deal 2 years plus ago on only Phase 2 results.
I understand Arcadia have North America rights for Rhetts and Fragile X and anything else Trofinetide can treat and NEU have also agreed not to market any other competing drug in NI in the Rhetts and Fragile X space.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.74 |
Change
0.150(1.03%) |
Mkt cap ! $1.842B | |||
| Open | High | Low | Value | Volume |
| $14.36 | $14.86 | $14.25 | $3.222M | 221.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 585 | $15.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.48 | 16 | 1 |
View Market Depth
| Last trade - 15.59pm 16/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |